Evidence mapPaperPMID 41486865Full record

ReviewAnnals of medicine2026

The ketogenic diet is not for everyone: contraindications, side effects, and drug interactions.

Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, Dorota Łojko, Hanna Karakuła-Juchnowicz, Georgia Ede, Żaneta Grzywacz, Katarzyna Antosik, Shebani Sethi, David Unwin

Abstract readReview
In one paragraph

Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Damian DyńkaInstitute of Health Sciences, Faculty of Medical and Health Sciences, University of Siedlce, Siedlce, Poland.
Łukasz RodzeńRodzen Brothers Foundation, Wieleń, Poland.
Mateusz RodzeńRodzen Brothers Foundation, Wieleń, Poland.
Dorota ŁojkoDepartment of Psychiatry, Poznan University of Medical Science, Poznan, Poland.
Hanna Karakuła-JuchnowiczDepartment of Psychiatry, Psychotherapy and Early Intervention, Medical University of Lublin, Poland.
Georgia EdeIndependent Researcher, Amesbury, Massachusetts, USA.
Żaneta GrzywaczFaculty of Production Engineering and Logistics, Opole University of Technology, Opole, Poland.
Katarzyna AntosikInstitute of Health Sciences, Faculty of Medical and Health Sciences, University of Siedlce, Siedlce, Poland.
Shebani SethiMetabolic Psychiatry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
David UnwinFaculty of Health Social Care and Medicine, Edge Hill University, Ormskirk, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ketogenic diet (KD), initially developed for the treatment of neurological disorders, has gained increasing attention for its potential role in the management of various metabolic diseases. Alongside its expanding clinical use, concerns have emerged regarding its safety, tolerability, and suitability in specific patient populations. This review summarises key contraindications, clinical situations requiring caution, relevant drug interactions, and commonly reported adverse effects associated with KD. DISCUSSION: Rare absolute contraindications include selected inborn errors of metabolism affecting pyruvate carboxylase activity, carnitine transport or utilisation, fatty acid oxidation pathways, as well as porphyria. Relative contraindications encompass acute pancreatitis, advanced hepatic or renal disease, familial hypercholesterolaemia, and other conditions that may be aggravated by KD-induced metabolic changes, including concomitant use of propofol. Particular caution is warranted in patients with type 1 or type 2 diabetes receiving specific glucose-lowering therapies, pharmacologically treated hypertension, gallbladder disease or prior cholecystectomy, electrolyte disturbances, cardiac arrhythmias, pregnancy or lactation, underweight status, intense physical activity, significant psychosocial stress, or postoperative recovery.Clinically relevant interactions with medications are reviewed, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, metformin, glucagon-like peptide-1 (GLP-1) receptor agonists, insulin and sulphonylurea derivatives, antiepileptic drugs, diuretics, lipophilic drugs, and corticosteroids. The most frequently reported adverse effects range from transient "keto flu" symptoms (fatigue, headache, nausea) to gastrointestinal disturbances, polyuria, and hypoglycaemia.

conclusionsKD demonstrates therapeutic potential in the management of a broad range of metabolic and neurological diseases; however, it is not an intervention suitable for all clinical situations. Awareness of existing contraindications, conditions requiring particular caution, and potential drug interactions enables a more responsible, individualised, and safe approach to patient selection and clinical management. In this context, the present paper provides a concise yet comprehensive synthesis to support clinicians and researchers in the rational and effective application of the ketogenic diet in both clinical practice and scientific research.

Indexed as

Diet, KetogenicMetabolic DiseasesContraindicationsDrug InteractionsHumansabsolute contraindicationsdiseasesdrug interactionsKetogenic diet (KD)relative contraindicationsside effects

Identifiers

PMID41486865
PMCPMC12777878

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.